One of the apoptotic resistance mechanisms in breast cancer stem cells (CSCs) is designed by the existence of tumorassociated macrophages (TAMs), type 2 macrophages. TAMs enhance the apoptotic resistance of CSCs by extremely decreasing low levels of inducible nitric oxide (iNO) and a reactive oxygen intermediate (ROI). On the other hand, heat shock protein-70 (Hsp-70) expression may modulate TAMs to upregulate those molecules. Typhonium flagelliforme (TF) tuber extract has an apoptotic activity through increasing iNO and ROI levels of cancer cells. However, the role of TF in increasing the Hsp-70 expression of TAMs leading to apoptosis improvement remains unclear. TAMs were produced by coculturing the human breast cancer-derived peripheral blood mononuclear cells with the CSCs. TAMs were assigned into two treatment groups consisting of one treatment group (treated by TF at 50.89 μg/ml) and the control group (medium administration only). The expression of Hsp-70 was analyzed by immunocytochemistry. This study found that Hsp-70 expression was shown to be significantly increased in TAMs. In conclusion, TF may promote the increase of Hsp-70 expression in TAMs. Hsp-70 as a promising drug target in cancer therapy for reducing resistance to cancer therapy has the potential to be developed and investigated further.
Key words: apoptosis resistance, CSCs, Hsp70, TAM, Typhonium flagelliforme.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
